



Solid Tumor Cancer Panel 50 Oncogene



ClearID is a blood test that provides physicians with actionable biomarker information from whole blood to help guide treatment and find ongoing clinical trials for aggressive, metastatic, and refractory cancer patients.

The solid tumor cancer panel targets 50 genes that, when mutated, have been associated with a variety of solid tumor cancers in clinical studies.

The Newest Generation in Liquid Biopsy Technology

ClearID™ uses Cynvenio's LiquidBiopsy® approach to tumor monitoring to analyze both circulating tumor cells (CTCs) and cell-free DNA (cfDNA) alongside the patient's healthy DNA (germline) to provide a clear distinction between tumor and germline.

This unique analysis of multiple templates increases test sensitivity to provide additional perspective on a patient's cancer and can be used in conjunction with tissue biopsies for more comprehensive analysis, or when biopsy material is unavailable, insufficient, or impractical to obtain.

Accurate, Reliable Results


ClearID has a negligible false positive rate (less than 0.0014%). While not every individual with disease will have target cells or mutations addressable by this test, ClearID has a zero false negative rate for patient samples known to have an addressable mutation. ClearID test specificity is 100% and its sensitivity is 98.4%.

ClearID test results are provided to the ordering physician within 10-14 days of receipt of the specimen.

A Path to Action

ClearID test results are summarized in a clear, actionable genomic report containing clinical interpretations of the identified biomarkers and variants, their associations with drugs, related clinical trials, and experimental therapies that can guide physicians, oncologists, and pathologists in making treatment decisions.

- ✔ Summary of cancer-associated mutations
- ✔ Recommended targeted therapies
- ✔ List of active clinical trials
- ✔ Supporting medical evidence contextualized by a network of oncologists and researchers



ClearID 50 Oncogene Panel*

5000+ Mutations Surveyed

TARGETED THERAPIES†

Saracatinib •

Triciribine, MK-2206, Ritonavir •

LDK378, Crizotinib, X-396 •

LGK974, WNT pathway inhibitors •

Trametinib, Vemurafenib, Dabrafenib, Cetuximab, MEK & RAS inhibitors •

Palbociclib, Dinaciclib •

Erlotinib, Panitumumab, Cetuximab, Neratinib, Gefitinib, Afatinib •

Trastuzumab, Lapatinib, Kadcyla, Pertuzumab, MGAH22, AMG 386, LJM 716, Neratinib, Ganestespib, MM-302 •

Dovotinib •

FGFR inhibitors and antibodies •

ENMD-2076 •

FLT3 •

Trametinib, MEK & RAS inhibitors •

Temozolomide, Decacarbazine •

ABL1

AKT1

ALK

APC

ATM

BRAF

CDH1

CDKN2A

CSF1R

CTNNB1

EGFR

ERBB2

ERBB4

EZH2

FBXW7

FGFR1

FGFR2

FGFR3

FLT3

GNA11

GNAQ

GNAS

HNF1A

HRAS

IDH1

IDH2

JAK2

JAK3

KDR

KIT

KRAS

MET

MLH1

MPL

NOTCH1

NPM1

NRAS

PDGFRA

PIK3CA

PTEN

PTPN11

RB1

RET

SMAD4

SMARCB1

SMO

SRC

STK11

TP53

VHL

• Ruxolitinib, JAK-STAT inhibitors, STAT decoys

• VEGF inhibitors & antibodies

• Pazopanib, Imatinib, Sunitinib

• Trametinib, Cetuximab, MEK & RAS inhibitors

• Cabozantinib, Crizotinib

• JAK-STAT inhibitors

• BMS-906024, RO4929097

• Trametinib, Cetuximab, MEK & RAS inhibitors

• Apatinib, Sunitinib, Sorafenib, Pazopanib, Imatinib

• BKM120, MK-2206, BYL719, BEZ235, GDC-0032, GDC-0941, GDC-0980, Everolimus, Temsirolimus, AMG479, CC-223, CC-122

• GSK2636771, MK-2206, PIK3 inhibitors

• RET inhibitors, Vandetanib

• Fresolimumab

• GDC-0449, LDE225, Hedgehog inhibitors

• Saracatinib, Dasatinib

• Sorafenib, Sunitinib, Pazopanib, Axitinib, Bevacizumab, Rapamycin, Everolimus, Temsirolimus

† Targeted therapy source: Breastcancertrials.org (updated 12/16). Select targeted therapies shown; not comprehensive of all agents in development. Includes investigational agents as well as commercialized drugs.

*Cynvenio also offers oncogene panels tailored for specific indications. Contact Cynvenio to learn more.

How to Order

1



Order a ClearID test kit from Cynvenio.

2



Schedule a patient blood draw.

3



Prepare and ship the sample to Cynvenio for analysis.

4



Interpretive test report is provided to the physician within 10-14 days.

Fasting is not required prior to a ClearID test.

Cynvenio works with all public and private payers. We perform pre-verification of benefits before starting testing, complete the authorization process on behalf of the patient, and do not balance bill. It is our philosophy that no patient should be prevented from receiving important diagnostic tests that lead to personalized therapy. Our **Cynvenio CARES program** ensures affordable access to our testing.

Please contact a member of our Client Services team at 888-885-1172 for more information or to order a test.